{"drugs":["Typhim Vi","Typhoid Vi Polysaccharide Vaccine","Typhoid Vi Polysaccharide Vaccine"],"mono":{"0":{"id":"923233-s-0","title":"Generic Names","mono":"Typhoid Vi Polysaccharide Vaccine"},"1":{"id":"923233-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923233-s-1-4","title":"Adult Dosing","mono":"<b>Typhoid fever; Prophylaxis:<\/b> 0.5 mL IM as a single dose; booster dose every 2 yr if re-exposure expected "},"1":{"id":"923233-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness have not been established in children below 2 years of age<\/li><li><b>Typhoid fever; Prophylaxis:<\/b> 2 yr and older, 0.5 mL IM as a single dose; booster dose every 2 yr if re-exposure expected<\/li><\/ul>"},"3":{"id":"923233-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Typhoid fever; Prophylaxis<br\/>"}}},"3":{"id":"923233-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923233-s-3-9","title":"Contraindications","mono":"hypersensitivity to vaccine components <br\/>"},{"id":"923233-s-3-10","title":"Precautions","mono":"<ul><li>acute infection or febrile illness; consider deferring vaccination<\/li><li>coagulation disorders, thrombocytopenia; intramuscular injection<\/li><li>continue to take precautions against exposure to typhoid organisms (i.e. avoid contact or ingestion of potentially contaminated food or water; vaccine protection is not universal<\/li><li>history of sensitivity to similar vaccines<\/li><li>impaired immune responsiveness; deficiency in ability to produce a humoral or cell-mediated immune response (either congenital or acquired immunodeficiency including treatment with immunosuppressive drugs or radiation)<\/li><li>special care should be taken to ensure that the vaccine is not injected into a blood vessel<\/li><li>vaccine adverse event reporting system: 1-800-822-7967, or http:\/\/www.vaers.org, and to manufacturer at 1-800-822-2463<\/li><\/ul>"},{"id":"923233-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>A (AUS)<\/li><\/ul>"},{"id":"923233-s-3-12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"4":{"id":"923233-s-4","title":"Drug Interactions","sub":{"1":{"id":"923233-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"923233-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Leflunomide (established)<\/li><\/ul>"}}},"5":{"id":"923233-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema (children 6.9%; adults 3% to 11%), Induration at injection site (children 2.9%; adults 5.1% to 18%), Injection site pain (children 14.3%; adults 26% to 56%), Tenderness, localized (children 13%; adults 93% to 98%)<\/li><li><b>Gastrointestinal:<\/b>Nausea (1.9% to 8.2%)<\/li><li><b>Musculoskeletal:<\/b>Myalgia (2% to 7.4%)<\/li><li><b>Neurologic:<\/b>Headache (11% to 27%)<\/li><li><b>Other:<\/b>Feeling feverish (children 2.9%; adults 3.1% to 11.1%), Malaise (4.1% to 37%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction<\/li><li><b>Other:<\/b>Serum sickness due to drug<\/li><\/ul>"},"6":{"id":"923233-s-6","title":"Drug Name Info","sub":{"0":{"id":"923233-s-6-17","title":"US Trade Names","mono":"<ul><li>Typhim Vi<\/li><li>Typhoid Vi Polysaccharide Vaccine<\/li><\/ul>"},"2":{"id":"923233-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"923233-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923233-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923233-s-7","title":"Mechanism Of Action","mono":"Typhoid Vi polysaccharide vaccine exerts its protective effect against Salmonella typhi, the pathogen of typhoid fever, by increasing the serum anti-capsular antibodies.<br\/>"},"9":{"id":"923233-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>(injection) for IM use only; do not give IV<br\/><\/li><li><b>Intramuscular<\/b><br\/><ul><li>immunization should occur at least two weeks prior to expected exposure<\/li><li>preferred injection site for adults is in the deltoid<\/li><li>preferred injection site for children is in either the deltoid or the vastus lateralis<\/li><\/ul><\/li><\/ul>"},"11":{"id":"923233-s-11","title":"How Supplied","mono":"<b>Typhim Vi<\/b><br\/>Intramuscular Solution: 25 MCG\/0.5 ML<br\/>"},"13":{"id":"923233-s-13","title":"Clinical Teaching","mono":"<ul><li>This vaccine may cause nausea, vomiting, myalgia, headache, fever, or malaise.<\/li><li>Advise patient that this immunization should occur at least 2 weeks prior to expected exposure.<\/li><\/ul>"}}}